Sei Investments Co. Reduces Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sei Investments Co. lessened its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 61,221 shares of the specialty pharmaceutical company's stock after selling 26,878 shares during the quarter. Sei Investments Co. owned 0.10% of Jazz Pharmaceuticals worth $7,541,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. Cinctive Capital Management LP bought a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $14,277,000. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock valued at $19,394,000 after purchasing an additional 100,112 shares in the last quarter. GW&K Investment Management LLC grew its stake in shares of Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock worth $57,142,000 after buying an additional 97,589 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock valued at $13,800,000 after buying an additional 93,422 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,736 shares of company stock worth $4,023,305. Company insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on JAZZ. Needham & Company LLC reissued a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. HC Wainwright raised their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Trading Down 8.9 %

Shares of NASDAQ:JAZZ traded down $10.78 during trading on Friday, reaching $110.04. 2,171,302 shares of the company were exchanged, compared to its average volume of 755,523. The business's fifty day simple moving average is $132.27 and its 200-day simple moving average is $122.91. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The firm has a market capitalization of $6.68 billion, a PE ratio of 15.50, a P/E/G ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.